The early US experience with biosimilar approvals suggests big pharma companies with established biologic product portfolios may have an advantage when it comes to the data needed to support their biosimilar dosing devices.
For the two most recently approved biosimilars – the TNF-inhibitors Erelzi (Sandoz Inc.’s etanercept-szzs) and Amjevita (Amgen Inc.’s...







